These tools incorporate various pathological and clinical variables together with the tumor expression of these molecular signatures (ER, Ki67, PR, and HER2) to predict survival with or without adjuvant therapy (Bartlett et al., 2016). The gene discussed is MKI67; the disease is neoplasm.